Advertisement

Impact of Nutrition on Medications for Osteoporosis

  • Jeri W. NievesEmail author
  • Felicia Cosman
Chapter
Part of the Nutrition and Health book series (NH)

Abstract

Nutrition is clearly important for skeletal health. Yet, in many cases, depending on bone density and fracture risk, nutrition alone is not enough, and pharmacologic treatment may be required to prevent bone loss and osteoporosis-related fractures. It is important to stress that nutrition still plays an important role even in individuals being treated for osteoporosis. There are a number of options for treatment of osteoporosis. Many of the available osteoporosis treatments are capable of improving bone mass by 1–10 % at various skeletal sites over 3–5 years. However, there must be an adequate nutritional supply of calcium and vitamin D in order to promote bone growth, similar to the amount that the skeleton needs during growth in childhood. The best approach is to reduce all possible risk factors, optimize nutrition, particularly calcium and vitamin D, and encourage an exercise program, which has an overall health benefit as well as impact on the skeleton and muscle. Pharmacologic therapies should be initiated in patients with osteoporosis and those at highest risk. Different pharmacologic therapies might be appropriate for women at different ages and according to their personal and family medical history. All pivotal phase III studies of the efficacy of treatments for osteoporosis have taken place in patients who were given calcium and vitamin D. There may be a minimal level of serum 25(OH)D required for optimal response to osteoporosis medication, likely between 25 and 33 ng/ml. The impact of calcium and vitamin D on pharmacologic therapy is inconsistent but in no cases was the efficacy reduced with adequate calcium and vitamin D. Therefore the recommendation to obtain adequate calcium and vitamin D through diet and/or supplements should maximize the beneficial effects of pharmacologic treatments.

Keywords

Calcium Vitamin D Osteoporosis medication 25(OH)D 

References

  1. 1.
    Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2012;97:1871–80.PubMedCrossRefGoogle Scholar
  2. 2.
    Nurmi-Luthje I, Sund R, Juntunen M, Luthje P. Post-hip fracture use of prescribed calcium plus vitamin D or vitamin D supplements and antiosteoporotic drugs is associated with lower mortality: a nationwide study in Finland. J Bone Miner Res. 2011;26:1845–53.PubMedCrossRefGoogle Scholar
  3. 3.
    Nieves JW, Komar L, Cosman F, Lindsay R. Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr. 1998;67:18–24.PubMedGoogle Scholar
  4. 4.
    Tuppurainen MT, Komulainen M, Kroger H, Honkanen R, Jurvelin J, Puntila E, Heikkinen AM, Alhava E, Saarikoski S. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen? Osteoporos Int. 1998;8:32–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Gorai I, Hattori S, Tanaka Y, Iwaoki Y. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Metab. 2012;30:349–58.PubMedCrossRefGoogle Scholar
  6. 6.
    Antoniucci DM, Vittinghoff E, Blackwell T, Black DM, Sellmeyer DE. Vitamin D insufficiency does not affect bone mineral density response to raloxifene. J Clin Endocrinol Metab. 2005;90:4566–72.PubMedCrossRefGoogle Scholar
  7. 7.
    Karaplis AC, Chouha F, Djandji M, Sampalis JS, Hanley DA. Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis. Ann Pharmacother. 2011;45:561–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr Med Res Opin. 2007;23:1341–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Shapses SA, Kendler DL, Robson R, Hansen KE, Sherrell RM, Field MP, Woolf E, Berd Y, Mantz AM, Santora 2nd AC. Effect of alendronate and vitamin D(3) on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women. J Bone Miner Res. 2011;26:1836–44.PubMedCrossRefGoogle Scholar
  10. 10.
    Antoniucci DM, Vittinghoff E, Palermo L, Black DM, Sellmeyer DE. Vitamin D insufficiency does not affect response of bone mineral density to alendronate. Osteoporos Int. 2009;20:1259–66.PubMedCrossRefGoogle Scholar
  11. 11.
    Olmos JM, Hernandez JL, Llorca J, Nan D, Valero C, Gonzalez-Macias J. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate. J Clin Endocrinol Metab. 2012;97:4491–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc. 2007;55:752–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Heckman GA, Papaioannou A, Sebaldt RJ, Ioannidis G, Petrie A, Goldsmith C, Adachi JD. Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates. BMC Musculoskelet Disord. 2002;3:6.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH)D level needed to maintain a favorable bisphosphonate response is >/=33 ng/ml. Osteoporos Int. 2012;23:2479–87.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Ishijima M, Sakamoto Y, Yamanaka M, Tokita A, Kitahara K, Kaneko H, Kurosawa H. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int. 2009;85:398–404.PubMedCrossRefGoogle Scholar
  16. 16.
    Peris P, Martinez-Ferrer A, Monegal A, de Osaba MJ M, Muxi A, Guanabens N. 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone. 2012;51:54–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Deane A, Constancio L, Fogelman I, Hampson G. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. BMC Musculoskelet Disord. 2007;8:3.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Recker R, Lips P, Felsenberg D, Lippuner K, Benhamou L, Hawkins F, Delmas PD, Rosen C, Emkey R, Salzmann G, He W, Santora AC. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. Curr Med Res Opin. 2006;22:1745–55.PubMedCrossRefGoogle Scholar
  19. 19.
    Schacht E, Ringe JD. Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective study. Arzneimittelforschung. 2011;61:40–54.PubMedCrossRefGoogle Scholar
  20. 20.
    Chung HY, Chin SO, Kang MI, Koh JM, Moon SH, Yoon BK, Yoon HK, Chung YS, Park HM. Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. Clin Endocrinol (Oxf). 2011;74:699–704.CrossRefGoogle Scholar
  21. 21.
    Bourke S, Bolland MJ, Grey A, Horne AM, Wattie DJ, Wong S, Gamble GD, Reid IR. The impact of dietary calcium intake and vitamin D status on the effects of zoledronate. Osteoporos Int. 2013;24:349–54.PubMedCrossRefGoogle Scholar
  22. 22.
    Catalano A, Morabito N, Atteritano M, Basile G, Cucinotta D, Lasco A. Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis. Calcif Tissue Int. 2012;90:279–85.PubMedCrossRefGoogle Scholar
  23. 23.
    Mosali P, Bernard L, Wajed J, Mohamed Z, Ewang M, Moore A, Fogelman I, Hampson G. Vitamin D status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab. Calcif Tissue Int. 2014;94(5):553–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Traina AN, Kane MP, Bakst G, Busch RS, Abelseth JM, Hamilton RA. Efficacy of teriparatide in patients with resolved secondary hyperparathyroidism due to vitamin D deficiency. Endocr Pract. 2011;17:568–73.PubMedCrossRefGoogle Scholar
  25. 25.
    Cosman F, Dawson-Hughes B, Wan X, Krege JH. Changes in vitamin D metabolites during teriparatide treatment. Bone. 2012;50:1368–71.PubMedCrossRefGoogle Scholar
  26. 26.
    Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE, Minisola S, Rossini M. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int. 2009;20:239–44.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of EpidemiologyColumbia UniversityNew YorkUSA
  2. 2.Helen Hayes HospitalWest HaverstrawUSA
  3. 3.Department of MedicineColumbia UniversityNew YorkUSA

Personalised recommendations